Ovarian suppression via Gonadotropin releasing hormone analog (GnRHa) treatment should remain as an unproven method of fertility preservation due to lack of biological plausibility, conflicting results, and design flaws in the studies which include the lack of placebo and blinding and the utility of improper surrogates for fertility and ovarian reserve
Background: Gonadotropin-releasing hormone agonists (GnRHa) might play a role in preserving ovarian ...
The addition of gonadotropin releasing hormone analog (GnRH-a) to controlled ovarian hyperstimulatio...
Fertility preservation: potential ovarian protective effect of GnRH analogues during chemotherap
Since the survival of patients with cancer has significantly improved, chemotherapy-related prematur...
Abstract Background The literature has always been controversial on the use of gonadotropin-releasin...
Does fertility preservation using gonadotrophin-releasing hormone (GnRH) analogues during chemothera...
The use of chemotherapy in premenopausal cancer patients may lead to chemotherapy-induced premature ...
Chemotherapy-induced premature ovarian insufficiency (POI) is one of the potential drawbacks of chem...
Survivorship issues are an area of crucial importance to be addressed as early as possible by all he...
In this review, we analyzed existing literature regarding the use of Gonadotropin-releasing Hormone ...
Chemotherapy may result in a detrimental effect on ovarian function and fertility in premenopausal w...
Background Recently, conservative surgery is acceptable in young patients with borderline ovarian tu...
Hikmat Abdel-RazeqDepartment of Internal Medicine, Section of Hematology and Medical Oncology, King ...
Gonadotropin-releasing hormone agonists (GnRHa) might play a role in preserving ovarian function in ...
Although use of gonadotropin-releasing hormone agonist (GnRHa) during chemotherapy is an established...
Background: Gonadotropin-releasing hormone agonists (GnRHa) might play a role in preserving ovarian ...
The addition of gonadotropin releasing hormone analog (GnRH-a) to controlled ovarian hyperstimulatio...
Fertility preservation: potential ovarian protective effect of GnRH analogues during chemotherap
Since the survival of patients with cancer has significantly improved, chemotherapy-related prematur...
Abstract Background The literature has always been controversial on the use of gonadotropin-releasin...
Does fertility preservation using gonadotrophin-releasing hormone (GnRH) analogues during chemothera...
The use of chemotherapy in premenopausal cancer patients may lead to chemotherapy-induced premature ...
Chemotherapy-induced premature ovarian insufficiency (POI) is one of the potential drawbacks of chem...
Survivorship issues are an area of crucial importance to be addressed as early as possible by all he...
In this review, we analyzed existing literature regarding the use of Gonadotropin-releasing Hormone ...
Chemotherapy may result in a detrimental effect on ovarian function and fertility in premenopausal w...
Background Recently, conservative surgery is acceptable in young patients with borderline ovarian tu...
Hikmat Abdel-RazeqDepartment of Internal Medicine, Section of Hematology and Medical Oncology, King ...
Gonadotropin-releasing hormone agonists (GnRHa) might play a role in preserving ovarian function in ...
Although use of gonadotropin-releasing hormone agonist (GnRHa) during chemotherapy is an established...
Background: Gonadotropin-releasing hormone agonists (GnRHa) might play a role in preserving ovarian ...
The addition of gonadotropin releasing hormone analog (GnRH-a) to controlled ovarian hyperstimulatio...
Fertility preservation: potential ovarian protective effect of GnRH analogues during chemotherap